A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab.

Xiaolin YunYingying ZhouDanna WuYuanbo LiuQiongshi Wu

Published in: Expert opinion on drug safety (2024)

Our study found potential new and unexpected AEs signals for daratumumab, suggesting prospective clinical studies are needed to confirm these results and illustrate their relationship.

Keyphrases

adverse drug

multiple myeloma

drug induced